The landscape of pharmaceutical innovation is undergoing a significant transformation. As someone who closely follows FDA Approves New Oral Peptide for Plaque Psoriasis advancements in biotechnology and molecular delivery, I have observed that the quest for an effective oral peptide approved delivery system has long been the "holy grail" of the industry. Historically, the structural instability of peptides in the gastrointestinal tract meant that most had to be administered via injection. However, recent breakthroughs are changing this narrative, proving that peptides can indeed be engineered for oral bioavailability.
Understanding the Shift toward Oral Delivery
The primary hurdle for any approved peptide has always been degradation by stomach enzymes and poor absorption across the intestinal wall. Yet, we are witnessing a new era. When we discuss an oral peptide, we are looking at molecules designed to survive these harsh environments.
One of the most notable milestones in this space is semaglutide, a glucagon-like peptide-1 receptor agonist. Its success in oral formulations has paved the way for a broader understanding of how to achieve systemic delivery. It is Currently, there are more than 200 approved ther- apeutic proteins and more than 100 peptides on the market, accounting for approximately 10% of the fascinating to see how more than 40 peptide-based drugs are approved globally, yet only 11 can be administered orally, highlighting the immense technical challenge researchers face.
Key Breakthroughs and Notable Agents
The recent approval of new agents has brought significant attention to this field. The most prominent example is ICOTYDE (Icotrokinra), which represents a massive leap forward. Icotrokinra is the first oral agent FDA approved to specifically target the IL-23 receptor, providing a mechanis Johnson & Johnson files for FDA approval of oral IL-23 inhibitor in psoriasis Oral peptide drugs, engineered to survive digestion and reach circulation m that mimics the efficacy of biologics.
* Icotrokinra (Icotyde; Johnson & Johnson): This oral macrocyclic IL-23 inhibitor nabs FDA approval for psoriasis in both adults and pediatric patients.
* Mycapssa: It is worth noting that Chiasma's Mycapssa is the first FDA-approved oral peptide for acromegaly, utilizing a unique permeability enhancer to achieve its therapeutic goals.
* Plecanatide: Plecanatide was developed by Synergy Pharmaceuticals and received FDA approval in 2017, showcasing that the foundation for these innovations was laid years ago.
Why the Industry Favors Peptides
From my perspective, the appeal of these compounds lies in their precision. Unlike small molecule drugs, peptides have less off-target effects due to their higher selectivity. They interact with receptors with a "lock and key" specif ICOTYDE (Icotrokinra) is the first oral peptide that precisely blocks the IL-23 receptor providing the potent efficacy observed with biologic icity that is difficult to replicate with traditional synthetic chemistry.
Furthermore, the convenience of a FDA-approved, once-daily oral icotrokinra regimen compared to previous parenteral requirements cannot be overstated. For those monitoring the market, seeing Johnson & Johnson file for FDA approval of oral IL-23 inhibitor in psoriasis was a clear signal that major players are heavily invested in the oral route.
Current Status and Future Outlook
When looking at the FDA-approved oral peptide formulations currently available, we see a heavy emphasis on macrocyclic structures, which provide the stability needed to survive digestion. Whether it is a drug approved for low-BSA and/or high-impact site psoriasis or treatments for metabolic conditions, the trend is clear: the industry is moving toward patient-centric, non-invasive delivery.
It is also important to remember that some older milestones, such as the product that was approved by the FDA in 2009, served as the initial proof-of-concept for oral bioavailability. Today ORAL PEPTIDE THERAPEUTICS , icotrokinra (Icotyde) stands as a testament to how far we have come. It is currently approved in the U.S. for specific patient populations, proving that when engineered correctly, these molecules New perspectives in oral peptide delivery are both safe and effective.
As the field matures, we will likely see more candidates move from clinical trials to market, further expanding the list of what is currently approved in the U.S. and beyond. The future of medicine is increa by AT Zizzari · 2021 · Cited by 114 — Oral-lyn™ is in Phase III clinical trials for T1DM (Table 1) and was approved by the FDA in 2009 for treatment of patients not eligible for Phase III clinical singly becoming an oral one May 8, 2025 — In 2023, three of the six approved peptide drugs were cyclic: Rezafungin (for candidemia), Motixafortide (targeting CXCR4 in multiple myeloma), , and the progress made with these targeted peptides is at the very heart of that movement.